Ontex's annual shareholders' meeting: All resolutions approved by a large majority
Aalst, Belgium, May 5, 2025 – Ontex Group NV, a leading international developer and producer of personal care products, held its annual shareholders' meeting today. All proposed resolutions were approved by the shareholders with a large majority of votes cast.
The minutes of the annual shareholders' meeting are available on Ontex's website at: https://ontex.com/agm-shareholder-information.
Enquiries
Investors Geoffroy Raskin +32 53 33 37 30 investor.relations@ontexglobal.com
Media Catherine Weyne +32 53 33 36 22 corporate.communications@ontexglobal.com
About Ontex
Ontex is a leading international developer and producer of baby care, feminine care and adult care products, for retailer and healthcare brands across Europe and North America. It employs about 5,500 people with plants and offices in 13 countries, and its innovative products are distributed in around 100 countries. The company is headquartered in Aalst, Belgium and is listed on Euronext Brussels, where it is a constituent of the Bel Mid® index. To keep up with the latest news, visit ontex.com or follow Ontex on LinkedIn.
Attachment
250505_AGMApproval_EN
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Meritage Homes Announces Quarterly Cash Dividend and $500M Increase to Share Repurchase Authorization
SCOTTSDALE, Ariz., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, 'Meritage' or the 'Company'), the fifth-largest homebuilder in the U.S., today announced that its Board of Directors has declared a quarterly dividend of $0.43 per share. This dividend is payable on September 30, 2025 to shareholders of record as of the close of trading on September 16, 2025. Meritage's Board of Directors has also approved a $500 million increase to the Company's share repurchase authorization. About Meritage Homes Corporation Meritage is the fifth-largest public homebuilder in the United States, based on homes closed in 2024. The Company offers energy-efficient and affordable entry-level and first move-up homes. Operations span across Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. Meritage has delivered over 200,000 homes in its 40-year history, and has a reputation for its distinctive style, quality construction, and award-winning customer experience. The Company is an industry leader in energy-efficient homebuilding, an eleven-time recipient of the U.S. Environmental Protection Agency's (EPA) ENERGY STAR® Partner of the Year for Sustained Excellence Award and Residential New Construction Market Leader Award, as well as a four-time recipient of the EPA's Indoor airPLUS Leader Award. For more information, visit Contacts: Emily Tadano, VP Investor Relations and External Communications (480) 515-8979 (office) investors@
Business Wire
6 hours ago
- Business Wire
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' Share 'Collaboration is at the core of the Quanterix Accelerator Laboratory,' said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. 'Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa ® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa ® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa ® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
